



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$35.02
Change (%)	▼ 0.47 (1.32%)
Volume	103,099
52 Week Low	\$24.47
Market Cap	\$1,462,598,513
Rolling EPS	1.39
PE Ratio	25.4968
Shares Outstanding	41,211,567

Data as of 08/18/17 12:36 p.m. ET



Recent Headlines & Events

08/03/17

Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance

07/31/17

Emergent BioSolutions Awarded \$23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense

07/26/17

Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva's Zika Vaccine Technology

SEC Filings

Filing Date	Form
08/17/17	4
08/14/17	CT ORDER
08/14/17	CT ORDER
08/10/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

Date	Title
08/31/17 3:10 p.m. ET	Emergent BioSolutions Inc. at Three Part Advisors 2017 Midwest IDEAS Investor Conference

Primary IR Contact

Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (240) 631 3280
Fax: (240) 413-1917
E-mail: burrowsr@ebsi.com